If it were my design(which it isn’t), I’d want at least two experimental arms. One with a lower Temodar dose to still interfere with DNA tumor cell repair but not high enough to interfere with DCVax-l instructed t-cells. (Arm 1) And a second arm with the same lower dose, but also shortened course of treatment. (Arm 2) (of course, both arms would also have DCVax-l)
It is conceivable the lowered dose of Temodar with regular DCVax-l dosing (Aka arm 1) might allow Temodar to function interrupting dna tumor cell repair over a longer period of time without efficacy decay, because it would not be interfering nearly as much with immune cell efficacy.